Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294465 | 0.79 | CA1 (0.38) | LMNASLC6A2SLC6A4SLC6A3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL4287068 | 0.78 | CA1 (0.37) | LMNASLC6A2SLC6A4SLC6A3HPGD | |
| SCHEMBL4281655 | 0.76 | KDM4E (0.52) | ALDH1A1MEN1KMT2ADRD3KDM4E | |
| SCHEMBL4286140 | 0.73 | HCRTR1 (0.44) | ALDH1A1KMT2ADRD3KDM4EMAPT | |
| SCHEMBL4284676 | 0.72 | MAPT (0.43) | LMNAALDH1A1KMT2AHPGDKDM4E | |
| SCHEMBL4290602 | 0.72 | HCRTR1 (0.39) | LMNAALDH1A1KMT2AKDM4EMAPT | |
| SCHEMBL4285817 | 0.72 | ALDH1A1 (0.45) | LMNAALDH1A1MEN1KMT2AOPRK1 | |
| SCHEMBL4292396 | 0.71 | ELANE (0.44) | LMNAALDH1A1KMT2AHPGDKDM4E | |
| SCHEMBL4295762 | 0.71 | PTGER4 (0.36) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL4289775 | 0.70 | HPGD (0.31) | ALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | LMNA 1785/4885SLC6A2 149/4885SLC6A4 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.